Shareholder Votes

Citi Trends Inc shareholders approved A proposal to approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as set forth in the Proxy Statement at the 2026-06-10 meeting.

“(2) A proposal to approve, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as set forth in the Proxy Statement: For Against Abstain Broker Non-Votes 6,652,352 59,072 5,695 604,211”

Citi Trends Inc shareholders approved Election of eight directors at the 2026-06-10 meeting.

“The voting results were as follows: (1) The election of eight directors: Board of Directors Nominee For Against Abstain Broker Non-Votes Pamela Edwards 4,268,634 2,443,138 5,347 604,211 Benjamin Faw 6,698,848 12,924 5,347 604,211 David A. Heath 6,698,071 13,701 5,347 604,211 Margaret L. Jenkins 6,645,741 66,031 5,347 604,211 Michael S. Kvitko 6,684,717 27,053 5,349 604,211 Chaoyang (Charles) Liu 6,689,004 22,766 5,349 604,211 Cara Robinson 6,677,190 34,583 5,346 604,211 Kenneth D. Seipel 6,700,829 10,943 5,347 604,211”

Terrestrial Energy Inc. /DE/ shareholders approved Ratification of appointment of UHY LLP as independent registered public accounting firm at the 2026-06-11 meeting.

“The Company’s stockholders ratified the appointment of UHY LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with votes cast as follows: ​ ​ For Against Abstain 69,103,315 400,853 165,166”

Terrestrial Energy Inc. /DE/ shareholders approved Election of three Class I directors at the 2026-06-11 meeting.

“The Company’s stockholders elected the three nominees to the Company’s Board of Directors to serve for three-year terms as Class I directors, with the votes cast as follows: ​ Director Name For Withheld Broker Non-Votes Frederick Buckman 56,661,573 303,610 12,704,151 William Johnson 56,668,879 296,304 12,704,151 Hugh MacDiarmid 56,662,842 302,341 12,704,151”

Marblegate Capital Corp shareholders approved Approval of adjournment or postponement of the annual meeting, if necessary, to solicit additional proxies at the 2026-06-11 meeting.

“Proposal 4: Approval of Adjournment or Postponement The stockholders approved the adjournment or postponement of the annual meeting, if necessary, to solicit additional proxies, if there were not sufficient votes in favor of the Board Proposal, the Equity Plan Proposal, or the Auditor Proposal. The results of the votes were as follows: Proposal Votes For Votes Against Abstentions Approval of an adjournment or postponement of the meeting, if necessary, to solicit additional proxies, if there are not sufficient votes in favor of the Board Proposal, Equity Plan Proposal or Auditor Proposal 261,416 1,007”

Marblegate Capital Corp shareholders approved Ratification of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-11 meeting.

“Proposal 3: Ratification of Independent Registered Public Accounting Firm The stockholders ratified the appointment of Deloitte & Touche LLP by the audit committee of the Board as the Company’s independent registered public accounting firm for the year ending December 31, 2026 (the “ Auditor Proposal ”). The results of the votes were as follows: Proposal Votes For Votes Against Abstentions Ratification of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 23,575 250”

Marblegate Capital Corp shareholders approved Approval and adoption of the 2026 Plan at the 2026-06-11 meeting.

“Proposal 2: Approval and Adoption of the 2026 Plan The stockholders approved and adopted the 2026 Plan (the “ Equity Plan Proposal ”). The results of the votes were as follows: Proposal Votes For Votes Against Abstentions Broker Non-Votes Approval and adoption of the 2026 Plan 292,663 845 1,235,796”

Marblegate Capital Corp shareholders approved Election of Directors at the 2026-06-11 meeting.

“Proposal 1: Election of Directors The stockholders elected each of the Company’s five director nominees, each to serve until the 2027 annual meeting of stockholders and thereafter until their successors are elected and qualified (the “ Board Proposal ”). The results of the votes were as follows: Proposal Votes For All Withheld All Broker Non-Votes Harvey Golub 68,388,143 225,000 1,235,796 Sarah E. Feinberg 68,163,143 450,000 1,235,796 Frederick C. Herbst 68,613,143 0 1,235,796 Meera Joshi 68,613,143 0 1,235,796 Andrew Milgram 68,601,894 11,249 1,235,796”

Sphere Entertainment Co. shareholders voted on Advisory (non-binding) vote on frequency of stockholder votes on executive compensation at the 2026-06-10 meeting.

“4. The Company’s Class A stockholders and Class B stockholders, voting together as a single class, voted on an advisory (non-binding) basis, on the frequency of stockholder votes on executive compensation. The votes regarding this proposal were as follows: Three Years Two Years One Year Abstain Broker Non-Votes 77,957,012 13,803 12,574,218 67,224 3,058,144”

Sphere Entertainment Co. shareholders approved Advisory (non-binding) vote on compensation of named executive officers at the 2026-06-10 meeting.

“3. The Company’s Class A stockholders and Class B stockholders, voting together as a single class, approved in an advisory (non-binding) vote the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: For Against Abstain Broker Non-Votes 85,248,065 5,299,126 65,066 3,058,144”

Sphere Entertainment Co. shareholders approved Ratification of appointment of independent registered public accounting firm at the 2026-06-10 meeting.

“2. The Company’s Class A stockholders and Class B stockholders, voting together as a single class, ratified the appointment of the Company’s independent registered public accounting firm for the year ending December 31, 2026. The votes regarding this proposal were as follows: For Against Abstain Broker Non-Votes 93,553,873 46,648 69,880 0”

Sphere Entertainment Co. shareholders approved Election of Directors at the 2026-06-10 meeting.

“1. The Company’s Class A stockholders elected the four directors listed below to the Board of Directors for a term to expire at the 2027 annual meeting and until their successors have been elected and qualified. The votes regarding this proposal were as follows: For Withheld Broker Non-Votes Joseph J. Lhota 13,723,204 8,226,042 3,053,615 Joel M. Litvin 17,918,465 4,030,781 3,053,615 Debra G. Perelman 17,926,501 4,022,745 3,053,615 John L. Sykes 13,571,974 8,377,272 3,053,615 The Company’s Class B stockholders elected the eleven directors listed below to the Board of Directors for a term to expire at the 2027 annual meeting and until their successors have been elected and qualified. The votes regarding this proposal were as follows: For Withheld Broker Non-Votes James L. Dolan 68,667,540 0 0 Charles P. Dolan 68,667,540 0 0 Kristin A. Dolan 68,667,540 0 0 Marianne Dolan Weber 68,667,540 0 0 Paul J. Dolan 68,667,540 0 0 Quentin F. Dolan 68,667,540 0 0 Ryan T. Dolan 68,667,540 0 0 Thomas C”

American Integrity Insurance Group, Inc. shareholders approved Approval, on an advisory basis, of the frequency of future advisory votes on named executive officer compensation. at the 2026-06-11 meeting.

“ONE YEAR TWO YEARS THREE YEARS ABSTENTIONS BROKER NON- VOTES 7,776,895 2,245 8,068,067 397,015 2,396,722”

American Integrity Insurance Group, Inc. shareholders approved Approval, on an advisory basis, of the compensation of the Company’s named executive officers. at the 2026-06-11 meeting.

“VOTES CAST FOR VOTES CAST AGAINST ABSTENTIONS BROKER NON- VOTES 15,682,721 333,313 228,188 2,396,722”

American Integrity Insurance Group, Inc. shareholders approved Ratification of the appointment of Forvis Mazars, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-11 meeting.

“VOTES CAST FOR VOTES CAST AGAINST ABSTENTIONS 18,636,869 832 3,243”

American Integrity Insurance Group, Inc. shareholders approved Election of the Class I director nominee, Steven Smathers, to the Company’s board of directors, to serve a full term of three years until the annual meeting of stockholders to be held in 2029 and until his successor shall have been duly elected and qualified or until his earlier death, resignation o at the 2026-06-11 meeting.

“NOMINEE VOTES CAST FOR VOTES CAST AGAINST ABSTENTIONS BROKER NON- VOTES Steven Smathers 11,654,530 4,589,613 79 2,396,722”

W. P. Carey Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-11 meeting.

“Proposal Four . The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. FOR AGAINST ABSTAIN BROKER NON-VOTES 172,777,010 12,710,399 511,537 0”

W. P. Carey Inc. shareholders approved Approval, on a non-binding, advisory basis, of the frequency of the Company’s executive compensation vote. at the 2026-06-11 meeting.

“Proposal Three . The approval, on a non-binding, advisory basis, of the frequency of the Company’s executive compensation vote. 1 YEAR 2 YEARS 3 YEARS ABSTAIN BROKER NON-VOTES 148,581,678 323,189 4,398,511 2,089,067 30,606,501”

W. P. Carey Inc. shareholders approved Approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers. at the 2026-06-11 meeting.

“Proposal Two . The approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers. FOR AGAINST ABSTAIN BROKER NON-VOTES 143,555,213 9,541,402 2,295,830 30,606,501”

W. P. Carey Inc. shareholders approved Election of nine nominees to the Board of Directors at the 2026-06-11 meeting.

“Proposal One. The election of the nine nominees listed in the Company’s Proxy Statement and set forth below to the Board of Directors of the Company, each to serve until the next annual meeting of stockholders. NAME OF NOMINEE FOR AGAINST ABSTAIN BROKER NON-VOTES Constantin H. Beier 151,875,388 1,859,158 1,657,899 30,606,501 Tonit M. Calaway 141,244,004 12,488,567 1,659,874 30,606,501 Peter J. Farrell 149,449,276 4,284,510 1,658,659 30,606,501 Robert J. Flanagan 152,454,277 1,280,032 1,658,136 30,606,501 Jason E. Fox 149,459,242 4,267,139 1,666,064 30,606,501 Rhonda O. Gass 152,093,256 1,642,920 1,656,269 30,606,501 Margaret G. Lewis 147,798,053 5,902,066 1,692,326 30,606,501 Christopher J. Niehaus 150,497,851 3,235,040 1,659,554 30,606,501 Elisabeth T. Stheeman 152,854,000 877,461 1,660,984 30,606,501”

Arcus Biosciences, Inc. shareholders approved The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement at the 2026-06-11 meeting.

“Proposal 3 : The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 94,920,421 9,337,368 29,741 13,573,227”

Arcus Biosciences, Inc. shareholders approved The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 at the 2026-06-11 meeting.

“Proposal 2 : The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026: Votes For Votes Against Abstentions 112,905,582 4,767,430 187,745”

Arcus Biosciences, Inc. shareholders approved The election of Class II directors to hold office until the 2029 Annual Meeting of Stockholders and until its successor is duly elected and qualified at the 2026-06-11 meeting.

“Proposal 1 : The election of Class II directors to hold office until the 2029 Annual Meeting of Stockholders and until its successor is duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Dietmar Berger, M.D., Ph.D. 85,949,508 18,338,022 13,573,227 David Lacey, M.D. 85,974,583 18,312,947 13,573,227 Nicole Lambert 92,653,341 11,634,189 13,573,227 Johanna Mercier 85,941,754 18,345,776 13,573,227”

GPGI, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-11 meeting.

“The vote with respect to the Auditor Ratification Proposal was as follows: For Against Abstain 262,162,349 5,694 8,328 Broker Non-Votes: N/A”

GPGI, Inc. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2026-06-11 meeting.

“The vote with respect to the advisory Say-on-Frequency Proposal was as follows: Every One (1) Year Every Two (2) Years Every Three (3) Years Abstain 250,019,750 66,861 56,241 75,093 Broker Non-Votes: 11,958,426”

GPGI, Inc. shareholders approved Advisory approval of the compensation of named executive officers (Say-on-Pay) at the 2026-06-11 meeting.

“The vote with respect to the advisory Say-on-Pay Proposal was as follows: For Against Abstain 231,699,270 18,439,834 78,841 Broker Non-Votes: 11,958,426”

GPGI, Inc. shareholders approved Election of four Class II directors at the 2026-06-11 meeting.

“The vote with respect to the election of each of the directors was as follows: Nominees For Withheld Joseph J. DeAngelo 249,815,353 402,592 Brian F. Hughes 244,650,151 5,567,794 Mark R. James 230,584,975 19,632,970 Thomas R. Knott 242,484,633 7,733,312 Broker Non-Votes: 11,958,426”

Playtika Holding Corp. shareholders approved Advisory vote on executive compensation at the 2026-06-11 meeting.

“Proposal 3 in the Proxy Statement, a proposal to approve, on an advisory (non-binding) basis, the compensation of Playtika’s named executive officers as described in the Proxy Statement, was approved by the following vote: Votes For Votes Against Abstentions Broker Non-Votes 222,787,175 14,186,995 98,404 15,995,016”

Playtika Holding Corp. shareholders approved Ratification of selection of Kost Forer Gabbay & Kasierer as independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-11 meeting.

“Proposal 2 in the Proxy Statement, a proposal to ratify the selection of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as Playtika’s independent registered public accounting firm for the year ending December 31, 2026, was approved by the following vote: Votes For Votes Against Abstentions Broker Non-Votes 250,698,822 1,484,654 884,114 —”

Playtika Holding Corp. shareholders approved Election of Directors at the 2026-06-11 meeting.

“All of the nominees for director listed in Proposal 1 in Playtika’s Definitive Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 16, 2026 (the “Proxy Statement”), were elected to serve on Playtika’s board of directors by the following vote: Name of Nominee Votes For Votes Against Votes Withheld Broker Non-Votes Robert Antokol 236,135,949 — 936,625 15,995,016 Marc Beilinson 224,224,315 — 12,848,259 15,995,016 Hong Du 233,826,942 — 3,245,632 15,995,016 Dana Gross 235,362,829 — 1,709,745 15,995,016 Tian Lin 236,106,153 — 966,421 15,995,016 Bing Yuan 223,147,982 — 13,924,592 15,995,016”

COMCAST CORP shareholders rejected A shareholder proposal to adopt a policy to have an independent chair, as described in the proxy statement, was not approved. at the 2026-06-10 meeting.

“(4) A shareholder proposal to adopt a policy to have an independent chair, as described in the proxy statement, was not approved.”

COMCAST CORP shareholders approved The advisory vote on our executive compensation, as described in the proxy statement, was approved. at the 2026-06-10 meeting.

“(3) The advisory vote on our executive compensation, as described in the proxy statement, was approved.”

COMCAST CORP shareholders approved The appointment of Deloitte & Touche LLP as our independent auditors for the 2026 fiscal year, as described in the proxy statement, was ratified. at the 2026-06-10 meeting.

“(2) The appointment of Deloitte & Touche LLP as our independent auditors for the 2026 fiscal year, as described in the proxy statement, was ratified.”

COMCAST CORP shareholders approved All of the director nominees named in the proxy statement were elected to serve as directors for one-year terms. at the 2026-06-10 meeting.

“(1) All of the director nominees named in the proxy statement were elected to serve as directors for one-year terms.”

Summit Therapeutics Inc. shareholders approved Approval of an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to increase the number of shares of the Company's common stock issuable under the Plan by 8,000,000 shares at the 2026-06-10 meeting.

“Proposal 4 For Against Abstain Broker Non-Votes Approval of an amendment to the Plan to increase the number of shares of the Company's common stock issuable under the Plan by 8,000,000 shares 619,799,393 27,247,910 124,199 30,576,341”

Summit Therapeutics Inc. shareholders approved Non-binding advisory vote to approve the compensation paid to the Company's named executive officers at the 2026-06-10 meeting.

“Proposal 3 For Against Abstain Broker Non-Votes Non-binding advisory vote to approve the compensation of named executive officers 622,624,328 24,445,791 101,383 30,576,341”

Summit Therapeutics Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.

“Proposal 2 For Against Abstain Broker Non-Votes Ratification of the appointment of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2026 677,302,337 85,284 360,222 —”

Summit Therapeutics Inc. shareholders approved Election of nine directors to serve until the Company's 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified at the 2026-06-10 meeting.

“Proposal 1 Election of Directors Director Nominees For Withheld Broker Non-Votes Robert W. Duggan 636,409,964 10,761,538 30,576,341 Mahkam Zanganeh 637,405,433 9,766,069 30,576,341 Manmeet Soni 636,690,652 10,480,850 30,576,341 Kenneth A. Clark 622,127,920 25,043,582 30,576,341 Robert Booth 646,257,923 913,579 30,576,341 Alessandra Cesano 646,263,718 907,784 30,576,341 Yu (Michelle) Xia 636,028,876 11,142,626 30,576,341 Mostafa Ronaghi 646,570,238 601,264 30,576,341 Jeff Huber 646,659,701 511,801 30,576,341”

Vor Biopharma Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2026-12-31 meeting.

“Proposal 3 - Ratification of Selection of Independent Registered Public Accounting Firm The Stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, by the following votes: For Against Abstain 33,877,004 133,499 1,501”

Vor Biopharma Inc. shareholders approved Amendment and Restatement of the Company's Amended and Restated 2021 Equity Incentive Plan.

“Proposal 2 - Amendment and Restatement of the Company's Amended and Restated 2021 Equity Incentive Plan The Stockholders approved the Amended 2021 Plan by the following votes. For Against Abstain Broker Non-Votes 20,146,430 6,767,428 4,036 7,094,110”

Vor Biopharma Inc. shareholders approved Election of Two Class II Directors Andrew Levin, M.D., Ph.D. and Fouad Namouni, M.D..

“Proposal 1 - Election of Two Class II Directors Andrew Levin, M.D., Ph.D. and Fouad Namouni, M.D. were each elected to serve as a member of the Board until the 2029 Annual Meeting of Stockholders and until his successor is duly elected or qualified, or, if sooner, until the director’s death, resignation or removal, by the following votes: Nominee For Withheld Broker Non-Votes Andrew Levin, M.D., Ph.D. 25,797,081 120,813 7,094,110 Fouad Namouni, M.D. 22,825938 4,091956 7,094,110”

Camp4 Therapeutics Corp shareholders approved Amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan at the 2026-06-10 meeting.

“3. The stockholders approved the amendment to the CAMP4 Therapeutics Corporation 2024 Equity Incentive Plan, based on the following votes: For Against Abstain Broker Non-Votes 27,002,145 10,023,588 199,455 2,773,446”

Camp4 Therapeutics Corp shareholders approved Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.

“2. The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026, based on the following votes: For Against Abstain 39,998,507 127 —”

Camp4 Therapeutics Corp shareholders approved Election of Class II directors at the 2026-06-10 meeting.

“1. The following nominees were elected as the Company’s Class II directors, each to serve for a three-year term until the 2029 annual meeting of stockholders, and until his successor shall have been duly elected and qualified, based on the following votes: Nominees For Against Abstain Broker Non-Votes Steven Holtzman 29,233,042 7,992,146 — 2,773,446 Murray Stewart, DM FRCP 31,669,512 5,555,665 11 2,773,446 Richard Young, PhD 29,212,962 8,012,214 12 2,773,446”

OptimizeRx Corp shareholders approved Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-09 meeting.

“5. Grant Thornton LLP was ratified as the Company’s independent registered public accounting firm for the 2026 fiscal year based upon the following votes: Votes in Favor Votes Against Abstain 15,750,329 27,585 14,338”

OptimizeRx Corp shareholders rejected Amendment to Equity Plan to adopt an evergreen provision for automatic annual increase in shares at the 2026-06-09 meeting.

“4. The amendment to the Equity Plan to adopt an evergreen provision providing for an automatic annual increase in the shares of Common Stock available for issuance under the Equity Plan was not approved based upon the following votes: Votes in Favor Votes Against Abstain Broker Non-Votes 5,627,324 7,001,699 24,773 3,138,456”

OptimizeRx Corp shareholders approved Amendment to Equity Plan to increase aggregate number of shares by 1,000,000 at the 2026-06-09 meeting.

“3. The amendment to the Equity Plan to increase the aggregate number of shares of Common Stock available for awards under the Equity Plan by 1,000,000 shares was approved based upon the following votes: Votes in Favor Votes Against Abstain Broker Non-Votes 11,541,123 1,096,197 16,476 3,138,456”

OptimizeRx Corp shareholders approved Advisory approval of named executive officer compensation at the 2026-06-09 meeting.

“2. The compensation of the Company’s named executive officers, as described in the proxy statement, was approved on an advisory basis based upon the following votes: Votes in Favor Votes Against Abstain Broker Non-Votes 11,660,549 895,095 98,152 3,138,456”

OptimizeRx Corp shareholders approved Election of seven directors to serve until next annual meeting at the 2026-06-09 meeting.

“1. The following nominees were each elected to serve as director for a term that expires at the next annual meeting of shareholders and until his or her successor has been elected and qualified or until his or her earlier death, resignation or removal based upon the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Lynn O’Connor Vos 8,327,850 4,325,946 3,138,456 Catherine Klema 9,079,088 3,574,708 3,138,456 James Lang 10,329,173 2,324,623 3,138,456 Patrick Spangler 8,092,151 4,561,645 3,138,456 Mariyamma Varghese Presti 11,766,568 887,228 3,138,456 Gregory Wasson 10,324,948 2,328,848 3,138,456 Stephen Silvestro 12,160,558 493,238 3,138,456 1”

DIVERSIFIED HEALTHCARE TRUST shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent auditors at the 2026-06-10 meeting.

“The Company’s shareholders also ratified the appointment of Deloitte & Touche LLP as the Company’s independent auditors to serve for the 2026 fiscal year. This proposal received the following votes: For Against Abstain Broker Non-Votes 202,537,283 221,495 103,717 N/A”